Comments
Generic and antiretroviral drug maker, Hetero, has launched generic Favipiravir in India under the brand name ‘Favivir.’
Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid patient population, which usually sustains mild to moderate symptoms.
Hetero’s Favivir is priced at ₹59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.
Backed by vertical integration capabilities, the drug is being manufactured at the formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others, the Hyderabad-based company said in a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.